Penumbra/PEN

$201.84

-3.27%
-
1D1W1MYTD1YMAX

About Penumbra

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Ticker

PEN

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Adam Elsesser

Employees

4,200

Headquarters

Alameda, United States

Penumbra Metrics

BasicAdvanced
$8.14B
Market cap
90.73
P/E ratio
$2.32
EPS
0.55
Beta
-
Dividend rate
$8.14B
0.54696
$348.67
$180.93
334.65K
6.056
3.489
2.009
2.198
76.427
6.21%
8.35%
6.91%
90.726
7.685
6.896
8.64
99.064
24.95%
4,427.95%
23.61%

What the Analysts think about Penumbra

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 13 analysts.
37.43% upside
High $320.00
Low $240.00
$201.84
Current price
$277.38
Average price target

Penumbra Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.04% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$284.6M
5.06%
Net income
$54.2M
489.13%
Profit margin
19.04%
461.65%

Penumbra Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.63%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.23
$0.43
$0.67
$0.76
-
Expected
$0.11
$0.28
$0.45
$0.70
$0.38
Surprise
111.17%
54.29%
47.32%
8.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Penumbra stock?

Penumbra (PEN) has a market cap of $8.14B as of April 19, 2024.

What is the P/E ratio for Penumbra stock?

The price to earnings (P/E) ratio for Penumbra (PEN) stock is 90.73 as of April 19, 2024.

Does Penumbra stock pay dividends?

No, Penumbra (PEN) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Penumbra dividend payment date?

Penumbra (PEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Penumbra?

Penumbra (PEN) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Penumbra stock price target?

The target price for Penumbra (PEN) stock is $277.38, which is 37.43% above the current price of $201.84. This is an average based on projections from 13 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Penumbra stock

Buy or sell Penumbra stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing